CLINICAL EVALUATION OF AGASHTYA HARITAKI RASAYANA AND APAMARGA KSHARA IN THE MANAGEMENT OF MILD STABLE BRONCHIAL ASTHMA (TAMAK SHWASA)

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex with age between 18 to 60 years.
•2.Diagnosed cases of the mild predominant or persistent stable Bronchial Asthma (Tamaka Shwasa) (as per GINA Guideline)
•(Stable asthma controller therapy dose i.e no changes in regular anti-asthma medication & Symptoms: <= 2 days/week; Night time awakenings: <= 2 times/month; Interference with normal activities: None; Short-acting Î²2-agonist use for symptom control: <= 2 days/week; for 3 months prior to enrolment).
•3.FEV1 >80% of the predicted value
•4.Patients willing to participate and written consent.

•1.Patients with FEV1 < 80% of the predicted value.
•2.Patients with uncontrolled Diabetes Mellitus having HbA1C > 8%
•3.Patients who have history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•4.Symptomatic patients with clinical evidence of Heart failure
•5.Known cases of HIV and AIDS.
•6.Known cases of malignancy
•7.Patient taking participation in any other clinical trial.
•8.Women who are planning for conception / pregnant or lactating.
•9.Patients with concurrent serious hepatic disorders (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease (COPD)
•10.H/o hypersensitivity to any of the trial drugs or their ingredients
•11.Any other condition which the Investigator thinks may jeopardize the study

发起方